British-Swedish drugs giant Astrazeneca, led by boss Pascal Soriot (pictured), is buying the rare diseases specialist as part of plans to expand into new lucrative areas of treatment.
Investors have had to be patient waiting for AIM-listed biotech Circassia Pharmaceuticals to come good, but things might now be turning in its favour. A recent trading update highlighted good sales growth while cash – another key metric for any early-stage biotech – was healthier than expected. Circassia was caught up last year in the … Read more